InteguRx Therapeutics

InteguRx is developing innovative transdermal drug delivery technology to address patients’ needs that are not met by current therapies. Our lead product is a transdermal gel which delivers the well-known anti-nauseant ondansetron, which we are developing for the treatment of pregnancy-induced nausea and vomiting, a disabling condition which afflicts 75-90% of all pregnant women for an average of 10 weeks. The company’s proprietary transdermal drug delivery platform achieves extraordinary (>400